دورية أكاديمية
أعرض في EDS

Cancer worry among BRCA1/2 pathogenic variant carriers choosing surgery to prevent tubal/ovarian cancer: course over time and associated factors.

التفاصيل البيبلوغرافية
العنوان: Cancer worry among BRCA1/2 pathogenic variant carriers choosing surgery to prevent tubal/ovarian cancer: course over time and associated factors.
المؤلفون: van Bommel MHD; Department of Obstetrics and Gynaecology, Radboud Institute for Health Sciences, Radboud University Medical Center, PO Box 9101, 6500 HB, Nijmegen, The Netherlands. Majke.vanBommel@radboudumc.nl., Steenbeek MP; Department of Obstetrics and Gynaecology, Radboud Institute for Health Sciences, Radboud University Medical Center, PO Box 9101, 6500 HB, Nijmegen, The Netherlands., IntHout J; Department for Health Evidence, Radboud Institute for Health Sciences, Radboud University Medical Center, PO Box 9101, 6500 HB, Nijmegen, The Netherlands., Hermens RPMG; Scientific Institute for Quality of Healthcare, Radboud Institute for Health Sciences, Radboud University Medical Center, PO Box 9101, 6500 HB, Nijmegen, The Netherlands., Hoogerbrugge N; Department of Human Genetics, Radboud University Medical Center, PO Box 9101, 6500 HB, Nijmegen, The Netherlands., Harmsen MG; Department of Obstetrics and Gynaecology, Radboud Institute for Health Sciences, Radboud University Medical Center, PO Box 9101, 6500 HB, Nijmegen, The Netherlands., van Doorn HC; Department of Gynaecology, Erasmus MC Cancer Clinic, 's-Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands., Mourits MJE; Department of Gynaecologic Oncology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands., van Beurden M; Center for Gynaecological Oncology Amsterdam (CGOA), Netherlands Cancer Institute/Antoni Van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands., Zweemer RP; Department of Gynaecological Oncology, UMC Utrecht Cancer Center, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands., Gaarenstroom KN; Department of Obstetrics and Gynaecology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands., Slangen BFM; Department of Obstetrics and Gynaecology, Maastricht University Medical Center, GROW-School for Oncology and Developmental Biology, P. Debyelaan 25, 6229 HX, Maastricht, The Netherlands., Brood-van Zanten MMA; Center for Gynaecological Oncology Amsterdam (CGOA), Netherlands Cancer Institute/Antoni Van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.; Center for Gynaecological Oncology Amsterdam (CGOA), AmsterdamUMC, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands., Vos MC; Gynaecologic Oncologic Center South Location Elisabeth-TweeSteden Hospital, Hilvarenbeekseweg 60, 5000 LC, Tilburg, The Netherlands., Piek JM; Gynaecologic Oncologic Center South Location Catharina Hospital, Department of Obstetrics and Gynaecology and Catharina Cancer Institute, Michelangelolaan 2, 5623 EJ, Eindhoven, The Netherlands., van Lonkhuijzen LRCW; Center for Gynaecological Oncology Amsterdam (CGOA), AmsterdamUMC, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands., Apperloo MJA; Department of Obstetrics and Gynaecology, Medical Center Leeuwarden, Henri Dunantweg 2, 8934 AD, Leeuwarden, The Netherlands., Coppus SFPJ; Department of Obstetrics and Gynaecology, Maxima Medical Center, De Run 4600, 5504 DB, Veldhoven, The Netherlands., Prins JB; Department of Medical Psychology, Radboud Institute F Or Health Sciences, Radboud University Medical Center, PO Box 9101, 6500 HB, Nijmegen, The Netherlands., Custers JAE; Department of Medical Psychology, Radboud Institute F Or Health Sciences, Radboud University Medical Center, PO Box 9101, 6500 HB, Nijmegen, The Netherlands., de Hullu JA; Department of Obstetrics and Gynaecology, Radboud Institute for Health Sciences, Radboud University Medical Center, PO Box 9101, 6500 HB, Nijmegen, The Netherlands.
المصدر: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2022 Apr; Vol. 30 (4), pp. 3409-3418. Date of Electronic Publication: 2022 Jan 08.
نوع المنشور: Clinical Trial; Journal Article; Multicenter Study
اللغة: English
بيانات الدورية: Publisher: Springer International Country of Publication: Germany NLM ID: 9302957 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1433-7339 (Electronic) Linking ISSN: 09414355 NLM ISO Abbreviation: Support Care Cancer Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Berlin : Springer International, c1993-
مواضيع طبية MeSH: Breast Neoplasms* , Ovarian Neoplasms*/genetics , Ovarian Neoplasms*/pathology , Ovarian Neoplasms*/surgery, BRCA1 Protein/genetics ; Female ; Genetic Predisposition to Disease ; Heterozygote ; Humans ; Mutation ; Prospective Studies ; Salpingectomy ; Salpingo-oophorectomy
مستخلص: Objective: High cancer risks, as applicable to BRCA1 and BRCA2 pathogenic variant (PV) carriers, can induce significant cancer concerns. We examined the degree of cancer worry and the course of this worry among BRCA1/2-PV carriers undergoing surgery to prevent ovarian cancer, and identified factors associated with high cancer worry.
Methods: Cancer worry was evaluated as part of the multicentre, prospective TUBA-study (NCT02321228) in which BRCA1/2-PV carriers choose either novel risk-reducing salpingectomy with delayed oophorectomy or standard risk-reducing salpingo-oophorectomy. The Cancer Worry Scale was obtained before and 3 and 12 months after surgery. Cancer worry patterns were analysed using latent class growth analysis and associated factors were identified with regression analysis.
Results: Of all 577 BRCA1/2-PV carriers, 320 (57%) had high (≥ 14) cancer worry pre-surgery, and 54% had lower worry 12 months post-surgery than pre-surgery. Based on patterns over time, BRCA1/2-PV carriers could be classified into three groups: persistently low cancer worry (56%), persistently high cancer worry (6%), and fluctuating, mostly declining, cancer worry (37%). Factors associated with persistently high cancer concerns were age below 35 (BRCA1) or 40 (BRCA2), unemployment, previous breast cancer, lower education and a more recent BRCA1/2-PV diagnosis.
Conclusions: Some degree of cancer worry is considered normal, and most BRCA1/2-PV carriers have declining cancer worry after gynaecological risk-reducing surgery. However, a subset of these BRCA1/2-PV carriers has persisting major cancer concerns up to 1 year after surgery. They should be identified and potentially offered additional support.
Clinical Trial Registration: The TUBA-study is registered at ClinicalTrials.gov since December 11th, 2014. Registration number: NCT02321228.
(© 2021. The Author(s).)
References: Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ et al (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317(23):2402–2416. (PMID: 10.1001/jama.2017.7112)
Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69(1):7–34. (PMID: 10.3322/caac.21551)
Lheureux S, Gourley C, Vergote I, Oza AM (2019) Epithelial ovarian cancer. Lancet 393(10177):1240–1253. (PMID: 10.1016/S0140-6736(18)32552-2)
IntegraalKankercentrumNederland. Richtlijn Borstkanker (English: Guideline Breastcancer). Published 01–03–2017. Accessed 15 Apr 2021.
Henderson JT, Webber EM, Sawaya GF (2018) Screening for ovarian cancer: updated evidence report and systematic review for the US preventive services task force. JAMA 319(6):595–606. (PMID: 10.1001/jama.2017.21421)
Oei AL, Massuger LF, Bulten J, Ligtenberg MJ, Hoogerbrugge N, de Hullu JA (2006) Surveillance of women at high risk for hereditary ovarian cancer is inefficient. Br J Cancer 94(6):814–819. (PMID: 10.1038/sj.bjc.6603015)
van der Velde NM, Mourits MJ, Arts HJ, de Vries J, Leegte BK, Dijkhuis G et al (2009) Time to stop ovarian cancer screening in BRCA1/2 mutation carriers? Int J Cancer 124(4):919–923. (PMID: 10.1002/ijc.24038)
IntegraalKankercentrumNederland. Richtlijn Erfelijk en Familiair Ovariumcarcinoom (English: Guideline Hereditary and Familial Ovarian Carcinoma). Published 06–15–2015. Accessed 6 Oct.
Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH et al (2001) Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 195(4):451–456. (PMID: 10.1002/path.1000)
Labidi-Galy SI, Papp E, Hallberg D, Niknafs N, Adleff V, Noe M et al (2017) High grade serous ovarian carcinomas originate in the fallopian tube. Nat Commun 8(1):1093. (PMID: 10.1038/s41467-017-00962-1)
Harmsen MG, Arts-de Jong M, Hoogerbrugge N, Maas AH, Prins JB, Bulten J et al (2015) Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study. BMC Cancer 15:593. (PMID: 10.1186/s12885-015-1597-y)
Rees G, Fry A, Cull A (2001) A family history of breast cancer: women’s experiences from a theoretical perspective. Soc Sci Med 52(9):1433–1440. (PMID: 10.1016/S0277-9536(00)00248-3)
Mirosevic S, Thewes B, van Herpen C, Kaanders J, Merkx T, Humphris G et al (2019) Prevalence and clinical and psychological correlates of high fear of cancer recurrence in patients newly diagnosed with head and neck cancer. Head Neck 41(9):3187–3200. (PMID: 10.1002/hed.25812)
Custers JAE, Gielissen MFM, Janssen SHV, de Wilt JHW, Prins JB (2016) Fear of cancer recurrence in colorectal cancer survivors. Support Care Cancer 24(2):555–562. (PMID: 10.1007/s00520-015-2808-4)
van de Wal M, van Oort I, Schouten J, Thewes B, Gielissen M, Prins J (2016) Fear of cancer recurrence in prostate cancer survivors. Acta Oncol 55(7):821–827. (PMID: 10.3109/0284186X.2016.1150607)
Custers JA, van den Berg SW, van Laarhoven HW, Bleiker EM, Gielissen MF, Prins JB (2014) The Cancer Worry Scale: detecting fear of recurrence in breast cancer survivors. Cancer Nurs 37(1):E44-50. (PMID: 10.1097/NCC.0b013e3182813a17)
Gonçalves V, Jayson G, Tarrier N (2008) A longitudinal investigation of psychological morbidity in patients with ovarian cancer. Br J Cancer 99(11):1794–1801. (PMID: 10.1038/sj.bjc.6604770)
Sharpe L, Turner J, Fardell JE, Thewes B, Smith AB, Gilchrist J et al (2019) Psychological intervention (ConquerFear) for treating fear of cancer recurrence: mediators and moderators of treatment efficacy. J Cancer Surviv 13(5):695–702. (PMID: 10.1007/s11764-019-00788-4)
Andersen MR, Smith R, Meischke H, Bowen D, Urban N (2003) Breast cancer worry and mammography use by women with and without a family history in a population-based sample. Cancer Epidemiol Biomarkers Prev 12(4):314–320. (PMID: 12692105)
Hurley KE, Miller SM, Costalas JW, Gillespie D, Daly MB (2001) Anxiety/uncertainty reduction as a motivation for interest in prophylactic oophorectomy in women with a family history of ovarian cancer. J Womens Health Gend Based Med 10(2):189–199. (PMID: 10.1089/152460901300039566)
Finch A, Metcalfe KA, Chiang J, Elit L, McLaughlin J, Springate C et al (2013) The impact of prophylactic salpingo-oophorectomy on quality of life and psychological distress in women with a BRCA mutation. Psychooncology 22(1):212–219. (PMID: 10.1002/pon.2041)
Lerman C, Daly M, Masny A, Balshem A (1994) Attitudes about genetic testing for breast-ovarian cancer susceptibility. J Clin Oncol 12(4):843–850. (PMID: 10.1200/JCO.1994.12.4.843)
Watson M, Duvivier V, Wade Walsh M, Ashley S, Davidson J, Papaikonomou M et al (1998) Family history of breast cancer: what do women understand and recall about their genetic risk? J Med Genet 35(9):731–738. (PMID: 10.1136/jmg.35.9.731)
Douma KF, Aaronson NK, Vasen HF, Gerritsma MA, Gundy CM, Janssen EP et al (2010) Psychological distress and use of psychosocial support in familial adenomatous polyposis. Psychooncology 19(3):289–298. (PMID: 10.1002/pon.1570)
Jung T, Wickrama KAS (2008) An introduction to latent class growth analysis and growth mixture modeling. Soc Pers Psychol Compass 2(1):302–317. https://doi.org/10.1111/j.1751-9004.2007.00054.x. (PMID: 10.1111/j.1751-9004.2007.00054.x)
IBM Corp. Released 2017. IBM SPSS Statistics for Windows VA, NY: IBM Corp.
Powell CB, Alabaster A, Le A, Stoller N, Armstrong MA, Raine-Bennett T (2020) Sexual function, menopausal symptoms, depression and cancer worry in women with BRCA mutations. Psychooncology 29(2):331–338. (PMID: 10.1002/pon.5253)
Metcalfe KA, Price MA, Mansfield C, Hallett DC, Lindeman GJ, Fairchild A et al (2020) Predictors of long-term cancer-related distress among female BRCA1 and BRCA2 mutation carriers without a cancer diagnosis: an international analysis. Br J Cancer 123(2):268–274. (PMID: 10.1038/s41416-020-0861-3)
Shigehiro M, Kita M, Takeuchi S, Ashihara Y, Arai M, Okamura H (2016) Study on the psychosocial aspects of risk-reducing salpingo-oophorectomy (RRSO) in BRCA1/2 mutation carriers in Japan: a preliminary report. Jpn J Clin Oncol 46(3):254–259. (PMID: 10.1093/jjco/hyv190)
Michelsen TM, Dørum A, Dahl AA (2009) A controlled study of mental distress and somatic complaints after risk-reducing salpingo-oophorectomy in women at risk for hereditary breast ovarian cancer. Gynecol Oncol 113(1):128–133. (PMID: 10.1016/j.ygyno.2008.12.024)
Lebel S, Beattie S, Arès I, Bielajew C (2013) Young and worried: age and fear of recurrence in breast cancer survivors. Health Psychol 32(6):695–705. (PMID: 10.1037/a0030186)
Linden W, Vodermaier A, Mackenzie R, Greig D (2012) Anxiety and depression after cancer diagnosis: prevalence rates by cancer type, gender, and age. J Affect Disord 141(2–3):343–351. (PMID: 10.1016/j.jad.2012.03.025)
de Graaf R, Ten Have M, van Gool C, van Dorsselaer S (2012) Prevalence of mental disorders, and trends from 1996 to 2009. Results from NEMESIS-2. Tijdschr Psychiatr 54(1):27–38. (PMID: 22237608)
Thewes B, Kaal SEJ, Custers JAE, Manten-Horst E, Jansen R, Servaes P et al (2018) Prevalence and correlates of high fear of cancer recurrence in late adolescents and young adults consulting a specialist adolescent and young adult (AYA) cancer service. Support Care Cancer 26(5):1479–1487. (PMID: 29168035)
Thewes B, Butow P, Bell ML, Beith J, Stuart-Harris R, Grossi M et al (2012) Fear of cancer recurrence in young women with a history of early-stage breast cancer: a cross-sectional study of prevalence and association with health behaviours. Support Care Cancer 20(11):2651–2659. (PMID: 10.1007/s00520-011-1371-x)
Douma KF, Bleiker EM, Vasen HF, Gundy CM, Aaronson NK (2011) Quality of life and consequences for daily life of familial adenomatous polyposis (FAP) family members. Colorectal Dis 13(6):669–677. (PMID: 10.1111/j.1463-1318.2010.02275.x)
Keller M, Jost R, Kadmon M, Wüllenweber HP, Haunstetter CM, Willeke F et al (2004) Acceptance of and attitude toward genetic testing for hereditary nonpolyposis colorectal cancer: a comparison of participants and nonparticipants in genetic counseling. Dis Colon Rectum 47(2):153–162. (PMID: 10.1007/s10350-003-0034-5)
Vos JR, Fakkert IE, de Hullu JA, van Altena AM, Sie AS, Ouchene H et al (2020) Universal tumor DNA BRCA1/2 testing of ovarian cancer: prescreening PARPi treatment and genetic predisposition. J Natl Cancer Inst 112(2):161–169. (PMID: 10.1093/jnci/djz080)
Curtis KM, Mohllajee AP, Peterson HB (2006) Regret following female sterilization at a young age: a systematic review. Contraception 73(2):205–210. (PMID: 10.1016/j.contraception.2005.08.006)
Burm R, Thewes B, Rodwell L, Kievit W, Speckens A, van de Wal M et al (2019) Long-term efficacy and cost-effectiveness of blended cognitive behavior therapy for high fear of recurrence in breast, prostate and colorectal cancer survivors: follow-up of the SWORD randomized controlled trial. BMC Cancer 19(1):462. (PMID: 10.1186/s12885-019-5615-3)
van de Wal M, Thewes B, Gielissen M, Speckens A, Prins J (2017) Efficacy of blended cognitive behavior therapy for high fear of recurrence in breast, prostate, and colorectal cancer survivors: the SWORD study, a randomized controlled trial. J Clin Oncol 35(19):2173–2183. (PMID: 10.1200/JCO.2016.70.5301)
Tauber NM, O’Toole MS, Dinkel A, Galica J, Humphris G, Lebel S et al (2019) Effect of psychological intervention on fear of cancer recurrence: a systematic review and meta-analysis. J Clin Oncol 37(31):2899–2915. (PMID: 10.1200/JCO.19.00572)
معلومات مُعتمدة: KUN 2014-7187 KWF Kankerbestrijding
فهرسة مساهمة: Keywords: BRCA gene; Cancer worry; Ovarian cancer; Psychology; Risk-reducing salpingo-oophorectomy; Salpingectomy
سلسلة جزيئية: ClinicalTrials.gov NCT02321228
المشرفين على المادة: 0 (BRCA1 Protein)
0 (BRCA1 protein, human)
تواريخ الأحداث: Date Created: 20220108 Date Completed: 20220222 Latest Revision: 20220812
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC8857097
DOI: 10.1007/s00520-021-06726-4
PMID: 34997316
قاعدة البيانات: MEDLINE
الوصف
تدمد:1433-7339
DOI:10.1007/s00520-021-06726-4